Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.39B P/E - EPS this Y -9.90% Ern Qtrly Grth -
Income -96.75M Forward P/E -13.64 EPS next Y -51.00% 50D Avg Chg -25.00%
Sales - PEG -1.56 EPS past 5Y - 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.60 EPS next 5Y 40.00% 52W High Chg -46.00%
Recommedations 1.50 Quick Ratio 37.55 Shares Outstanding 110.80M 52W Low Chg 449.00%
Insider Own 6.03% ROA -11.57% Shares Float 104.78M Beta 1.00
Inst Own 75.17% ROE -14.80% Shares Shorted/Prior 15.91M/17.70M Price 13.91
Gross Margin - Profit Margin - Avg. Volume 2,851,827 Target Price 113.55
Oper. Margin - Earnings Date Oct 23 Volume 1,253,300 Change -1.77%
About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc. News
12/24/24 Will Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?
12/24/24 3 biggest catalysts expected for healthcare in 2025
12/23/24 Is Viking Therapeutics, Inc. (VKTX) the Best Performing Biotech Stock in 2024?
12/23/24 Hot Obesity Drug Market Will Keep Investors Gripped Next Year
12/21/24 Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
12/21/24 My Top 10 Stocks to Buy for 2025
12/20/24 Why Viking Therapeutics Tumbled by More Than 10% This Week
12/20/24 Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
12/20/24 Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.
12/20/24 Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
12/20/24 Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
12/19/24 Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
12/19/24 Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
12/19/24 Here's Why VKTX Stock Plummeted 18% on Wednesday
12/18/24 Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else
12/18/24 Why Viking Therapeutics (VKTX), HEICO Corporation (HEI), and ABM Industries (ABM) Stocks Are Plunging Today?
12/18/24 What's Going On With Viking Therapeutics Stock On Wednesday?
12/18/24 Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.
12/17/24 Is Viking Therapeutics, Inc. (VKTX) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
12/16/24 Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lian Brian President & CEO President & CEO Jan 31 Sell 24.7 85,000 2,099,500 2,264,882 01/31/24
Lian Brian President & CEO President & CEO Jan 31 Option 1.23 85,000 104,550 2,349,882 01/31/24
Lian Brian President & CEO President & CEO Jan 30 Sell 23.95 35,000 838,250 2,264,882 01/30/24
Lian Brian President & CEO President & CEO Jan 30 Option 1.23 35,000 43,050 2,299,882 01/30/24
Rouan Sarah Kathryn Director Director Jan 19 Sell 23.05 30,000 691,500 01/19/24
Rouan Sarah Kathryn Director Director Jan 19 Option 8.32 30,000 249,600 30,000 01/19/24
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 17.9 15,000 268,500 180,730 01/04/24
Rowland Charles A Jr Director Director May 16 Option 1.08 40,000 43,200 70,000 05/18/23
Rowland Charles A Jr Director Director May 16 Sell 25 40,000 1,000,000 30,000 05/18/23
MACARTNEY LAWSON Director Director May 16 Sell 24 16,000 384,000 47,965 05/18/23
MACARTNEY LAWSON Director Director May 16 Option 1.19 16,000 19,040 63,965 05/18/23
Lian Brian President & CEO President & CEO May 01 Sell 22.45 45,000 1,010,250 2,197,963 05/01/23
MACARTNEY LAWSON Director Director Apr 24 Sell 22 16,000 352,000 47,965 04/24/23
MACARTNEY LAWSON Director Director Apr 24 Option 3.33 16,000 53,280 63,965 04/24/23
Lian Brian President & CEO President & CEO Apr 19 Sell 21.45 35,000 750,750 2,242,963 04/21/23
MACARTNEY LAWSON Director Director Apr 17 Sell 20 20,786 415,720 47,965 04/18/23
MACARTNEY LAWSON Director Director Apr 17 Option 8 20,786 166,288 68,751 04/18/23
Lian Brian President & CEO President & CEO Apr 17 Sell 20.45 155,000 3,169,750 2,277,963 04/18/23
Lian Brian President & CEO President & CEO Apr 17 Option 2.15 125,000 268,750 2,432,963 04/18/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Apr 17 Sell 20 12,500 250,000 287,763 04/18/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Apr 17 Option 13.07 12,500 163,375 300,263 04/18/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 17 Sell 20 7,500 150,000 149,279 04/18/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 17 Option 13.07 7,500 98,025 156,779 04/18/23
Lian Brian President & CEO President & CEO Apr 13 Sell 18.45 79,336 1,463,749 2,307,963 04/13/23
Lian Brian President & CEO President & CEO Apr 13 Option 1.88 54,336 102,152 2,387,299 04/13/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 11 Sell 18 97,839 1,761,102 149,279 04/13/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 11 Option 6.12 97,839 598,775 190,823 04/13/23
Lian Brian President & CEO President & CEO Mar 30 Sell 17.43 243,352 4,241,625 2,232,963 04/03/23
Lian Brian President & CEO President & CEO Mar 30 Option 6.74 203,352 1,370,592 2,322,933 04/03/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Mar 30 Sell 17.5 161,940 2,833,950 147,778 04/03/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Mar 30 Option 6.55 124,661 816,530 178,689 04/03/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 30 Option 9.92 72,200 716,224 261,895 04/03/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 28 Sell 15.5 237,805 3,685,978 261,895 03/30/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 28 Option 2.98 182,427 543,632 303,137 03/30/23